News | News By Subject | News by Disease News By Date | Search News

Hemophilia A News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Roche (RHHBY) Reports Death in Phase III Hemophilia Study     2/23/2017
Roche (RHHBY) Takes a Win as Emicizumab Hemophilia Drug Succeeds in Phase III     12/22/2016
Sources Reveal Biogen (BIIB) is Exploring Sale of Hemophilia Assets     4/12/2016
FDA Gives Thumbs Up to Bayer (BAY)'s Hemophilia A Drug Kovaltry     3/17/2016
FDA Green Lights Octapharma USA's NUWIQ for Hemophilia A     9/15/2015
Genentech (RHHBY)’s Hemophilia A Drug Gets Breakthrough Designation in Potential $11 Billion Market     9/10/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review     3/17/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Baxter International, Inc. (BAX)'s Hemophilia A Drug Obizur Wins FDA Approval     10/24/2014
Long-Acting Version Of Baxter International, Inc. (BAX)'s Hemophilia A Drug BAX 855 Succeeds In Study     8/21/2014
Baxter International, Inc. (BAX) Opens Its First State-Of-The-Art Biologics Facility In Asia     8/11/2014
FDA Approves Biogen, Inc.'s Hemophilia A Drug Eloctate     6/9/2014
FDA Approves Bayer HealthCare (BAY)'s Kogenate® FS Antihemophilic Factor VIII (Recombinant) For Routine Prophylaxis In Adults With Hemophilia A     5/12/2014

News from Around the Web

Press Releases
BioMarin (BMRN) Receives Access To Priority Medicines (PRIME) Regulatory Support From EMA For BMN 270 Gene Therapy In Hemophilia A     2/2/2017
Swedish Orphan Biovitrum Release: First Patients Enrolled In 24 Month Real-World Study Evaluating Effectiveness Of Elocta     1/19/2017
BioMarin (BMRN) Release: Bay Area Biotech Solidifies Status as Top Dog in Hemophilia A Gene Therapy     1/10/2017
CSL Behring Release: AFSTYLA, For Haemophilia A, Receives European Commission Approval     1/9/2017
HEMA Biologics Announced Today The Acceptance By FDA Of The Submitted Biologic License Application For Coagulation Factor Viia Recombinant, (Eptacog Beta Activated)     1/9/2017
Sangamo (SGMO) Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A     1/5/2017
Health Canada Approves CSL Behring's AFSTYLA For The Treatment Of Hemophilia A     12/15/2016
Sangamo (SGMO) Presents Hemophilia A Program Data At The 2016 American Society of Hematology Meeting     12/6/2016
Alnylam (ALNY) Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors     12/5/2016
Swedish Orphan Biovitrum: Elocta Approved in Kuwait For The Treatment Of Hemophilia A     11/21/2016
CSL Behring Release: AFSTYLA, For Haemophilia A, Receives Positive Opinion From EMA CHMP     11/14/2016
Octapharma USA Announces Two Hemophilia A Clinical Trials To Utilize WILATE     11/14/2016
Chugai Pharma's Emicizumab Showed Continued Benefits In Patients With Hemophilia A     7/28/2016
CSL Behring Presents Pivotal Efficacy Data For AFSTYLA In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress     7/27/2016
Sangamo (SGMO) Announces New Gene Therapy Clinical Development Program for Treatment Of Hemophilia A     7/26/2016

//-->